OncoCyte (OCX) Competitors

Cardio Diagnostics (NASDAQ:CDIO) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.

Is CDIO or OCX more profitable?

Cardio Diagnostics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -1,890.62%. Cardio Diagnostics' return on equity of -96.30% beat OncoCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	N/A	-293.34%	-131.96%
OncoCyte	-1,890.62%	-96.30%	-41.12%

Which has more volatility and risk, CDIO or OCX?

Cardio Diagnostics has a beta of 5.03, indicating that its share price is 403% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of CDIO or OCX?

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 55.4% of OncoCyte shares are owned by institutional investors. 30.0% of Cardio Diagnostics shares are owned by insiders. Comparatively, 1.9% of OncoCyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media refer more to CDIO or OCX?

In the previous week, OncoCyte had 4 more articles in the media than Cardio Diagnostics. MarketBeat recorded 7 mentions for OncoCyte and 3 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.34 beat OncoCyte's score of -0.67 indicating that OncoCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
OncoCyte	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer CDIO or OCX?

Cardio Diagnostics presently has a consensus target price of $1.35, suggesting a potential upside of 86.88%. OncoCyte has a consensus target price of $4.06, suggesting a potential upside of 66.50%. Given OncoCyte's stronger consensus rating and higher probable upside, analysts plainly believe Cardio Diagnostics is more favorable than OncoCyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
OncoCyte	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has preferable valuation and earnings, CDIO or OCX?

Cardio Diagnostics has higher earnings, but lower revenue than OncoCyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$20K	779.83	-$8.38M	N/A	N/A
OncoCyte	$1.50M	13.45	-$27.78M	N/A	N/A

Does the MarketBeat Community favor CDIO or OCX?

OncoCyte received 3 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Cardio Diagnostics an outperform vote while only 8.33% of users gave OncoCyte an outperform vote.

Company	Underperform	Outperform
Cardio Diagnostics	Outperform Votes 2 66.67%	Underperform Votes 1 33.33%
OncoCyte	Outperform Votes 5 8.33%	Underperform Votes 55 91.67%

Summary

Cardio Diagnostics beats OncoCyte on 8 of the 15 factors compared between the two stocks.